PMC:7128678 / 3604-4624 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"117","span":{"begin":477,"end":482},"obj":"Gene"},{"id":"118","span":{"begin":484,"end":485},"obj":"Gene"},{"id":"119","span":{"begin":581,"end":582},"obj":"Gene"},{"id":"120","span":{"begin":32,"end":37},"obj":"Species"},{"id":"121","span":{"begin":38,"end":51},"obj":"Species"},{"id":"122","span":{"begin":503,"end":513},"obj":"Species"},{"id":"123","span":{"begin":850,"end":860},"obj":"Species"},{"id":"124","span":{"begin":954,"end":959},"obj":"Species"},{"id":"125","span":{"begin":960,"end":973},"obj":"Species"},{"id":"126","span":{"begin":1004,"end":1014},"obj":"Species"},{"id":"127","span":{"begin":123,"end":134},"obj":"Chemical"},{"id":"128","span":{"begin":164,"end":176},"obj":"Chemical"},{"id":"129","span":{"begin":398,"end":410},"obj":"Chemical"},{"id":"130","span":{"begin":414,"end":425},"obj":"Chemical"},{"id":"131","span":{"begin":814,"end":832},"obj":"Chemical"},{"id":"132","span":{"begin":834,"end":840},"obj":"Chemical"},{"id":"133","span":{"begin":915,"end":921},"obj":"Chemical"}],"attributes":[{"id":"A117","pred":"tao:has_database_id","subj":"117","obj":"Gene:43740568"},{"id":"A118","pred":"tao:has_database_id","subj":"118","obj":"Gene:43740568"},{"id":"A119","pred":"tao:has_database_id","subj":"119","obj":"Gene:43740568"},{"id":"A120","pred":"tao:has_database_id","subj":"120","obj":"Tax:9606"},{"id":"A121","pred":"tao:has_database_id","subj":"121","obj":"Tax:11118"},{"id":"A122","pred":"tao:has_database_id","subj":"122","obj":"Tax:2697049"},{"id":"A123","pred":"tao:has_database_id","subj":"123","obj":"Tax:2697049"},{"id":"A124","pred":"tao:has_database_id","subj":"124","obj":"Tax:9606"},{"id":"A125","pred":"tao:has_database_id","subj":"125","obj":"Tax:11118"},{"id":"A126","pred":"tao:has_database_id","subj":"126","obj":"Tax:2697049"},{"id":"A127","pred":"tao:has_database_id","subj":"127","obj":"MESH:D019158"},{"id":"A128","pred":"tao:has_database_id","subj":"128","obj":"MESH:D005732"},{"id":"A129","pred":"tao:has_database_id","subj":"129","obj":"MESH:D012794"},{"id":"A130","pred":"tao:has_database_id","subj":"130","obj":"MESH:D005732"},{"id":"A131","pred":"tao:has_database_id","subj":"131","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T83","span":{"begin":32,"end":37},"obj":"SP_6;NCBITaxon:9606"},{"id":"T84","span":{"begin":38,"end":51},"obj":"NCBITaxon:11118"},{"id":"T85","span":{"begin":82,"end":90},"obj":"GO:0016020"},{"id":"T86","span":{"begin":123,"end":134},"obj":"CHEBI:26667;CHEBI:26667"},{"id":"T87","span":{"begin":146,"end":159},"obj":"CHEBI:17089;CHEBI:17089;BV_11"},{"id":"T88","span":{"begin":164,"end":176},"obj":"CHEBI:5386;CHEBI:5386"},{"id":"T89","span":{"begin":226,"end":243},"obj":"UBERON:0000065"},{"id":"T90","span":{"begin":398,"end":404},"obj":"CHEBI:30563;CHEBI:30563"},{"id":"T91","span":{"begin":405,"end":410},"obj":"CHEBI:41865;CHEBI:41865"},{"id":"T92","span":{"begin":414,"end":425},"obj":"CHEBI:28892;CHEBI:28892"},{"id":"T93","span":{"begin":426,"end":438},"obj":"SO:0000409"},{"id":"T94","span":{"begin":457,"end":463},"obj":"SO:0000417"},{"id":"T95","span":{"begin":487,"end":499},"obj":"CHEBI:17089;CHEBI:17089;BV_11"},{"id":"T96","span":{"begin":503,"end":513},"obj":"SP_7"},{"id":"T97","span":{"begin":583,"end":594},"obj":"CHEBI:28892;CHEBI:28892"},{"id":"T98","span":{"begin":645,"end":650},"obj":"NCBITaxon:10239;GO:0006260"},{"id":"T99","span":{"begin":651,"end":662},"obj":"GO:0006260"},{"id":"T100","span":{"begin":693,"end":703},"obj":"GO:0009986"},{"id":"T101","span":{"begin":704,"end":715},"obj":"GO:0045333;CL:0000100"},{"id":"T102","span":{"begin":716,"end":721},"obj":"CL:0000100"},{"id":"T103","span":{"begin":739,"end":748},"obj":"PG_1"},{"id":"T104","span":{"begin":814,"end":832},"obj":"CHEBI:5801;DG_20;CHEBI:5801"},{"id":"T105","span":{"begin":850,"end":860},"obj":"SP_7"},{"id":"T106","span":{"begin":954,"end":959},"obj":"SP_6;NCBITaxon:9606"},{"id":"T107","span":{"begin":960,"end":973},"obj":"NCBITaxon:11118"},{"id":"T108","span":{"begin":1004,"end":1014},"obj":"SP_7"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T18","span":{"begin":74,"end":81},"obj":"Body_part"},{"id":"T19","span":{"begin":82,"end":99},"obj":"Body_part"},{"id":"T20","span":{"begin":146,"end":159},"obj":"Body_part"},{"id":"T21","span":{"begin":164,"end":176},"obj":"Body_part"},{"id":"T22","span":{"begin":226,"end":243},"obj":"Body_part"},{"id":"T23","span":{"begin":414,"end":425},"obj":"Body_part"},{"id":"T24","span":{"begin":487,"end":499},"obj":"Body_part"},{"id":"T25","span":{"begin":583,"end":594},"obj":"Body_part"},{"id":"T26","span":{"begin":716,"end":721},"obj":"Body_part"},{"id":"T27","span":{"begin":741,"end":748},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma0326969"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma265130"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":226,"end":243},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T18","span":{"begin":465,"end":468},"obj":"Disease"},{"id":"T20","span":{"begin":503,"end":511},"obj":"Disease"},{"id":"T21","span":{"begin":850,"end":858},"obj":"Disease"},{"id":"T22","span":{"begin":1004,"end":1012},"obj":"Disease"}],"attributes":[{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0008449"},{"id":"A19","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0018075"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T23","span":{"begin":32,"end":37},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T24","span":{"begin":82,"end":90},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T25","span":{"begin":273,"end":274},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T26","span":{"begin":337,"end":339},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T27","span":{"begin":412,"end":413},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T28","span":{"begin":554,"end":555},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T29","span":{"begin":716,"end":721},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T30","span":{"begin":954,"end":959},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T31","span":{"begin":975,"end":981},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T39","span":{"begin":74,"end":81},"obj":"Chemical"},{"id":"T40","span":{"begin":130,"end":134},"obj":"Chemical"},{"id":"T41","span":{"begin":146,"end":159},"obj":"Chemical"},{"id":"T42","span":{"begin":164,"end":176},"obj":"Chemical"},{"id":"T43","span":{"begin":398,"end":410},"obj":"Chemical"},{"id":"T44","span":{"begin":405,"end":410},"obj":"Chemical"},{"id":"T45","span":{"begin":414,"end":425},"obj":"Chemical"},{"id":"T46","span":{"begin":487,"end":499},"obj":"Chemical"},{"id":"T47","span":{"begin":583,"end":594},"obj":"Chemical"},{"id":"T48","span":{"begin":741,"end":748},"obj":"Chemical"},{"id":"T49","span":{"begin":768,"end":777},"obj":"Chemical"},{"id":"T50","span":{"begin":814,"end":832},"obj":"Chemical"}],"attributes":[{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_26667"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T5","span":{"begin":645,"end":662},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T6","span":{"begin":645,"end":662},"obj":"http://purl.obolibrary.org/obo/GO_0019058"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T28","span":{"begin":0,"end":249},"obj":"Sentence"},{"id":"T29","span":{"begin":250,"end":411},"obj":"Sentence"},{"id":"T30","span":{"begin":412,"end":750},"obj":"Sentence"},{"id":"T31","span":{"begin":751,"end":875},"obj":"Sentence"},{"id":"T32","span":{"begin":876,"end":1020},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}

{"project":"2_test","denotations":[{"id":"32251731-23873408-48149940","span":{"begin":245,"end":247},"obj":"23873408"},{"id":"32251731-28205163-48149941","span":{"begin":337,"end":339},"obj":"28205163"},{"id":"32251731-16439323-48149942","span":{"begin":985,"end":986},"obj":"16439323"},{"id":"32251731-29940786-48149943","span":{"begin":990,"end":991},"obj":"29940786"},{"id":"T35411","span":{"begin":245,"end":247},"obj":"23873408"},{"id":"T47978","span":{"begin":337,"end":339},"obj":"28205163"},{"id":"T17061","span":{"begin":985,"end":986},"obj":"16439323"},{"id":"T81743","span":{"begin":990,"end":991},"obj":"29940786"}],"text":"One important characteristic of human coronaviruses is that besides their protein membrane receptor, they also depend upon sialic-acid-containing glycoproteins and gangliosides that act as primary attachment factors along the respiratory tract [10]. The present study used a combination of structural and molecular modelling approaches [11] to investigate the potential interaction between CLQ and sialic acids. A ganglioside-binding site in the N-terminal domain (NTD) of the spike (S) glycoprotein of SARS-CoV-2 was identified, and CLQ was shown to be a potential blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e. attachment to the surface of respiratory cells, mediated by the S protein). In addition, the antiviral potential of CLQ and its derivative hydroxychloroquine (CLQ-OH) against SARS-CoV-2 were compared. Overall, this study found that CLQ and CLQ-OH may be used to fight pathogenic human coronaviruses [3], [4], [5], [6], including SARS-CoV-2 [12]."}